Source comparison
BPC-157 Results After 1 Week: Dosing Protocol Comparison
Subcutaneous (near injury site) 250–500 mcg daily 30–40% reduction in local swelling by day 5–7 15–30% reduction in pain intensity VEGF upregulation measurable; no structural repair yet Most effective for localized injuries; results appear fastest but remain p
This comparison does not assign a generated winner or score.
- Subcutaneous (near injury site)
- 250–500 mcg daily
- 30–40% reduction in local swelling by day 5–7
- 15–30% reduction in pain intensity
- VEGF upregulation measurable; no structural repair yet
- Most effective for localized injuries; results appear fastest but remain preparatory, not curative
- Intramuscular (distant site)
- 500–750 mcg daily
- 20–30% reduction by day 7–9
- 10–20% reduction by day 7–9
- Systemic distribution delays onset but covers multiple sites
- Slower onset than subcutaneous; useful for multi-site injuries but one-week results are minimal
- Oral (capsule)
- 500–1000 mcg daily
- 15–25% reduction by day 10–12
- Minimal change in first week
- Gastric absorption slows systemic availability
- Least effective for acute injuries; week-one results are negligible in most protocols